Pneumococcal conjugate second or third-dose vaccines (PCVc) in Libya
Libya: Pneumococcal conjugate second or third-dose vaccines (PCVc) was 92.0% in 2025. ◆ Volatile
Latest (2025)
92.0%
Change on year
up 3.4%
World rank
56th
of 194 countries
All-time high
96.0%
in 2016
All-time low
0.0%
in 2008
Years of data
18
2008–2025
Pneumococcal conjugate second or third-dose vaccines (PCVc) in Libya, 2008–2025
Source: World Health Organization, Global Health Observatory.
Analysis
In 2025, pneumococcal conjugate second or third-dose vaccines (pcvc) in Libya stood at 92.0%.
Compared with earlier readings it is up 3.4% on the previous year and up 29.6% over ten years.
Over the whole period, pneumococcal conjugate second or third-dose vaccines (pcvc) in Libya peaked at 96.0% in 2016 and was at its lowest, 0.0%, in 2008.
Libya ranks 56th of 194 countries on this measure, in the middle of the range.
The series is highly variable year to year, so single readings are best treated with caution.
Pneumococcal conjugate second or third-dose vaccines (PCVc) in Libya, year by year
| Year | Value | Change |
|---|---|---|
| 2008 | 0.0% | — |
| 2009 | 0.0% | — |
| 2010 | 0.0% | — |
| 2011 | 0.0% | — |
| 2012 | 0.0% | — |
| 2013 | 0.0% | — |
| 2014 | 39.0% | — |
| 2015 | 71.0% | +82.1% |
| 2016 | 96.0% | +35.2% |
| 2017 | 95.0% | -1.0% |
| 2018 | 72.0% | -24.2% |
| 2019 | 73.0% | +1.4% |
| 2020 | 73.0% | +0.0% |
| 2021 | 73.0% | +0.0% |
| 2022 | 73.0% | +0.0% |
| 2023 | 73.0% | +0.0% |
| 2024 | 89.0% | +21.9% |
| 2025 | 92.0% | +3.4% |
Libya compared with similar countries
- Libya's 92.0% is above the median for upper middle income countries, which is 76.0%, 1.2× the median. (57 countries reporting)
- Libya's 92.0% is above the median for Middle East, North Africa, Afghanistan & Pakistan, which is 91.0%, 1.0× the median. (23 countries reporting)
Averages by decade
| Decade | Average | Lowest | Highest | Years |
|---|---|---|---|---|
| 2000s | 0.0% | 0.0% | 0.0% | 2 |
| 2010s | 44.6% | 0.0% | 96.0% | 10 |
| 2020s | 78.8% | 73.0% | 92.0% | 6 |
Countries ranked near Libya
More health data for Libya
- Un projection of annual infant deaths, annual growth rate -1.48 % change on previous year (2100)
- Heat deaths vs projected death rates, annual growth rate 1.1 % change on previous year (2090)
- Estimated changes in temperature-related death rates compared to projected death rates 1,084 deaths per 1,000 people (2090)
- Number of infants who die before age 1 133 deaths (2100)
- Neonatal tetanus - number of reported cases, gaps filled 0 (2024)
- Population ages 00-04, female, annual growth rate -1.83 % change on previous year (2025)
- Population ages 00-04, female, per unit of GDP 0 units per US$ of GDP (2025)
- Population ages 00-04, female, per capita 0.0404 units per person (2025)
- Population ages 00-04, male, annual growth rate -1.77 % change on previous year (2025)
- Population ages 00-04, male, per unit of GDP 0 units per US$ of GDP (2025)
Frequently asked questions
- What is pneumococcal conjugate second or third-dose vaccines (pcvc) in Libya?
- Pneumococcal conjugate second or third-dose vaccines (pcvc) in Libya was 92.0% in 2025, according to World Health Organization, Global Health Observatory.
- What is the highest pneumococcal conjugate second or third-dose vaccines (pcvc) recorded in Libya?
- The highest recorded value was 96.0% in 2016.
- What is the lowest pneumococcal conjugate second or third-dose vaccines (pcvc) recorded in Libya?
- The lowest recorded value was 0.0% in 2008.
- How does Libya rank for pneumococcal conjugate second or third-dose vaccines (pcvc)?
- Libya ranks 56th out of 194 countries with data for 2025.
- Is pneumococcal conjugate second or third-dose vaccines (pcvc) rising or falling in Libya?
- Over the last ten years it is up 29.6%. The long-run trend across the full record is volatile.
- Where does this Libya data come from?
- The figures come from World Health Organization, Global Health Observatory, published as part of Pneumococcal conjugate second or third-dose vaccines (PCVc) immunization coverage by the locally recommended age (%) (WUENIC). Statizoid updates them automatically from the source API.
Download this data
CSV · JSON — 18 observations, free to reuse under CC BY-NC-SA 3.0 IGO (WHO).